BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim Corporation for Drug Discovery Under a Non-Exclusive Agreement


1/17/2012 7:11:58 AM

SEATTLE, Jan. 17, 2012 /PRNewswire/ -- CompleGen, Inc. announced today that they have executed a non-exclusive services agreement regarding CompleGen's XenoGene technology. Boehringer Ingelheim's discovery team will apply the technology to explore targets that are not easily accessible by other discovery platforms.

CompleGen's XenoGene technology uses the power of genetics to identify allosteric inhibitors that are selective for specific protein targets.

"We are very pleased to be working with Boehringer Ingelheim to open pathways for therapeutics that have proved to be elusive previously," commented Pauline Gee, CompleGen's VP Business Development.

About CompleGen

CompleGen is a drug discovery company that uses its proprietary discovery platform, XenoGene technology to identify and develop selective inhibitors for difficult targets. With its small molecule library, CompleGen has identified potent allosteric inhibitors for targets where other discovery platforms have failed. These allosteric inhibitors have been shown to be efficacious and well tolerated in animals. www.complegen.com

Contact:
Pauline Gee, PhD
Vice President, Business Development
CompleGen, Inc.
1124 Columbia Street, Suite 662
Seattle, WA 98104
pgee@complegen.com
+1.303.961.1773

SOURCE CompleGen, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES